Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.

OBJECTIVE To compare the abilities of different ex vivo methods of treating donor lymphocytes to inhibit graft-vs-host disease (GVHD) while preserving graft-vs-leukemia (GVL) activity in murine models of allogeneic bone marrow transplantation. METHODS Donor/recipient pairs included MHC fully mismatched, MHC haplomismatched, and MiHA mismatched strain combinations. T cell-depleted BM (TCD-BM) was transplanted in combination with untreated, fludarabine-treated, 7.5-Gy gamma-irradiated, or psoralen/UVA (PUVA)-treated splenocytes. GVL activity was studied by adding a lethal number of recipient-type lymphoma cells. Posttransplant survival was determined, and GVHD and GVL activity were assessed by clinical and pathological scoring. Hematopoietic chimerism and donor T-cell expansion were analyzed by flow cytometry of peripheral blood samples at 30 and 60 days posttransplant. RESULTS Allogeneic splenocytes treated with fludarabine, 7.5 Gy gamma-irradiation, or PUVA had significantly diminished GVHD activity, and all treated donor T cells facilitated engraftment by low-dose TCD-BM. Allogeneic splenocytes treated with fludarabine and, to a lesser extent, PUVA retained GVL activity and contributed more to donor T-cell chimerism compared to gamma-irradiated donor splenocytes. CONCLUSION Among ex vivo methods of treating donor T cells to limit their proliferative capacity, fludarabine exposure had the greatest differential ability to inhibit the GVHD activity of allogeneic lymphocytes, while preserving their GVL activity and ability to engraft recipients. Thus, ex vivo treatment with fludarabine was superior to gamma-irradiation or PUVA in separating GVL from GVHD activity in murine models of allogeneic bone marrow transplantation.

• Publication year

  2006

• Venue

  Experimental Hematology

• Publication date

  2006-02-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1016/J.BBMT.2005.11.199PMID 16797417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.

  2005cited by this paper
• Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion.

  2004cited by this paper
• Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease.

  2004cited by this paper
• Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.

  2004cited by this paper
• Reconstructing immunity after allogeneic transplantation

  2004cited by this paper
• Pleasant memories: remembering immune protection while forgetting about graft-versus-host disease.

  2003cited by this paper
• Allogeneic T Cells Treated with Amotosalen Prevent Lethal Cytomegalovirus Disease without Producing Graft-versus-Host Disease Following Bone Marrow Transplantation 1

  2003cited by this paper
• ‘GVHD’: graft-versus-host disease or graft-versus-Hodgkin's disease? an old acronym with new meaning

  2003cited by this paper
• Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.

  2003cited by this paper
• Recent advances in allogeneic hematopoietic stem-cell transplantation.

  2003cited by this paper
• Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.

  2003cited by this paper
• Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality

  2003cited by this paper
• Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft

  2003cited by this paper
• Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation.

  2003cited by this paper
• Memory CD4+ T cells do not induce graft-versus-host disease.

  2003cited by this paper
• Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.

  2002cited by this paper
• Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells.

  2002cited by this paper
• Anti-CD3 epsilon F(ab')2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens.

  2001cited by this paper
• Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes.

  2001cited by this paper
• Th2 and Tc2 Cells in the Regulation of GVHD, GVL, and Graft Rejection: Considerations for the Allogeneic Transplantation Therapy of Leukemia and Lymphoma

  2000cited by this paper
• New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells

  2000cited by this paper
• Clinical use of irradiated donor lymphocytes in bone marrow transplantation.

  1999cited by this paper
• Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation.

  1999cited by this paper
• Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease.

  1999cited by this paper
• Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.

  1999cited by this paper
• IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.

  1999cited by this paper
• Prevention of transfusion-associated graft-versus-host disease by photochemical treatment.

  1999cited by this paper
• Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease.

  1998cited by this paper
• Photopheresis in paediatric patients with drug‐resistant chronic graft‐versus‐host disease

  1997cited by this paper
• Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long‐wavelength ultraviolet light

  1997cited by this paper
• Recent advances in graft‐versus‐host disease (GVHD) prevention

  1997cited by this paper
• The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.

  1997cited by this paper
• PUVA Treatment Selectively Induces a Cell Cycle Block and Subsequent Apoptosis in Human T‐Lymphocytes

  1996cited by this paper
• Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.

  1996cited by this paper
• An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin.

  1996cited by this paper
• Systemic treatment for cutaneous lymphomas.

  1995cited by this paper
• Rapid and sustained hematopoietic recovery in lethally irradiated mice transplanted with purified Thy-1.1lo Lin-Sca-1+ hematopoietic stem cells.

  1994cited by this paper
• Selective inactivation of lymphocytes after psoralen/ultraviolet light (PUVA) treatment without affecting systemic immune responses

  1993cited by this paper
• Purine nucleoside modulation of functions of human lymphocytes.

  1990cited by this paper
• Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.

  1989cited by this paper

• Efficacy of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation for 40 Cases with Severe Aplastic Anemia

  2019cites this paper
• Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies

  2015cites this paper
• Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy

  2014cites this paper
• Selective allodepletion to improve anti-viral and anti-leukaemic responses after haploidentical transplantation

  2009cites this paper
• Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.

  2009cites this paper
• Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

  2009cites this paper
• Dichotomous role of interferon-gamma in allogeneic bone marrow transplant.

  2009cites this paper
• Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.

  2006cites this paper